• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regenxbio Inc (NQ: RGNX )

    10.90 +0.08 (+0.74%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 417,514
    Open 10.92
    Bid (Size) 10.90 (1)
    Ask (Size) 12.95 (1)
    Prev. Close 10.82
    Today's Range 10.53 - 10.95
    52wk Range 10.50 - 28.80
    Shares Outstanding 43,466,186
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Is Clearside Biomedical Stock Gaining Today?
    Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
    Via Benzinga
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace

    Performance

    YTD
    -40.57%
    -40.57%
    1 Month
    -20.78%
    -20.78%
    3 Month
    -43.20%
    -43.20%
    6 Month
    -24.52%
    -24.52%
    1 Year
    -44.02%
    -44.02%

    More News

    Read More
    FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
    Via Benzinga
    Exposures Product Safety
    Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
    Via Investor's Business Daily
    Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
    Via Investor's Business Daily
    Exposures Product Safety
    Assessing Regenxbio: Insights From 4 Financial Analysts
    Via Benzinga
    Evaluating Regenxbio: Insights From 9 Financial Analysts
    Via Benzinga
    Where Regenxbio Stands With Analysts
    Via Benzinga
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Via Benzinga
    RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
    Via The Motley Fool
    This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
    Via Benzinga
    Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
    Via Benzinga
    Regenxbio: Q4 Earnings Insights
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    A Preview Of Regenxbio's Earnings
    Via Benzinga
    REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
    Via Benzinga
    The One-Minute Market Report - Sunday, Feb. 11
    Via Talk Markets
    Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
    Via Benzinga
    Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.